富春股份(300299.SZ):公司遊戲產品《仙境傳説RO:新世代的誕生》和字節跳動相關企業進行合作
格隆匯5月24日丨富春股份(300299.SZ)在5月22-23日電話會議表示,公司和字節跳動及相關企業的合作進展情況如下:1、公司遊戲產品《仙境傳説RO:新世代的誕生》和字節跳動相關企業進行合作,並在港澳台、東南亞、韓國等地區取得優異的成績。公司後續將陸續在其他區域上線該產品;2、公司與字節跳動相關企業量子躍動在2021年初共同增資蓋姆艾爾;3、公司看好VR/AR等新興技術在遊戲場景應用的長期發展前景,後續持續關注行業設備出貨量的變化,並保持與包括字節跳動相關方在內的市場主流VR/AR設備平台的商務對接。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.